Subhi Y, et al. - A total of 81 individuals were studied to evaluate the relation of the proportion of CD11b⁺ circulating monocytes with the number of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). They calculated the future number of anti-VEGF injections at 12, 24, and 36 months with the proportion of CD11b⁺ monocytes at baseline positively. They also observed the same relationship in subjects with neovascular AMD at 12, 24, and 36 months and cases with PCV at 12, 24, and 36 months. They suggested the association not precise to AMD but somewhat reflecting the VEGF activity in neovascularization. They noted CD11b⁺ monocytes (highly expressive of CCR2) as a significant monocytic marker of proangiogenic activity.